SpheriSome Hb, the novel blood substitute under development at Spheritech has now been approved for grant in the US. This is an extremely important stage following on from our successful kidney perfusion and functional maintenance early this year.
CAR T-cell therapy (27th August 2019)
Chimeric antigen receptor T-cells (CAR T cells) are T-cells where the DNA has been engineered to produce a modified T-cell receptor for use in immunotherapy. The T-cells are normally captured and activated using polystyrene based magnetic microparticles, which are expensive and can cause issues during T-cell isolation for return to the donor. At Spheritech we are developing a macroporous biopolymer cartridge with immobilised antibodies for T-cell activation. This simplifies the whole process from activation through to T-cell recovery. We hope to launch a range of T-cell activation cartridges in the next 6-8 months.
Removal of Arsenic from bore hole water (20th August 2019)
The high levels of arsenic in some domestic water supplies is beginning to raise concerns with water companies. In a number of rural areas where water often originates from bore holes or ground water wells the arsenic levels have on occasion exceeded the WHO maximum recommended levels. Spheritech are developing scalable, environmentally safe technology to reduce arsenic levels in domestic water supplies.
Linkage grant (19th August)
Spheritech has been awarded a $583,000 grant to work with the University of Melbourne on water based peptide synthesis
ISO9001:2015 certification (19th August 2019)
Following a successful audit our ISO9001:2015 certification has been extended for another 3 years.
New technology for sealing leaks in water pipes (19th August 2019)
We are now developing novel technology for sealing water leaks in mains supply pipes. For more information please contact us through our contacts page.
Lead in bore hole water reduced to legal limits (9th August 2019)
Spheritech has developed novel technology to remove lead from originating water sources (e.g. bore hole water). The technology is scalable to multi-tonne scale using well established engineering equipment.
SpheriTech develops novel blood substitute (9th August 2019)
The holy grail of the healthcare industry is often said to be the development of artificial blood. Replacement of donated blood for trauma and surgery with a blood substitute could save many lives and improve the lives of those with blood disorders. Many groups have developed haemoglobin based oxygen carriers (HBOCs) which inevitably lead to kidney damage or even complete renal failure. We have developed a HBOC, SpheriSome Hb where the haemoglobin is encapsulated in a fatty acid capsule, in essence generating artificial red blood cells. SpheriSome Hb has now been shown by the NHS to maintain oxygenation and carbon dioxide removal better than autologous blood in ex-vivo porcine kidney models, where the kidney has been shown to function normally and produce urine.
Spheritech develops a novel biopolymer for removal of lead from domestic water supplies (9th August 2019)
Lead levels in many households exceed legal limits and more importantly it has been reported that many schools in the UK and USA also exceed limits. In a 1993 DEFRA report some UK schools had lead levels of up to 80ppb which exceeds current legal limit 8-fold and one sampling point had lead levels >150ppb. In working to combat this issue Spheritech are developing a range of novel macroporous biopolymers for removal of lead from domestic water supplies in collaboration with the UK water industry. These can be in the form of a cartridge for in consumer households and schools or in a form suitable for large scale removal of lead from source water.